Evidence map›Paper›PMID 42785937›Full record

Observational studyBMJ open2026

Multimodality detection of early relapse in radically treated high-risk HPV-negative head and neck squamous cell carcinoma: study protocol for a prospective multicentre UK cohort study (HERD).

Sanjena Mithra, Ahmed Abdullah Ahmed, Amit Roshan, Paul R Barber, Camila de Carvalho Gomes, Ton Coolen, Elinor Sawyer, Nitzan Rosenfeld, Ralph Sinkus, Miguel Reis-Ferreira and 20 more

Registry-linked trialAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05097625 (A Prospective Cohort Study of Patients With Radically Treated Newly Diagnosed Locally Advanced HPV Negative Head and Neck Cancer to Develop and Validate a Multimodal Signature to Risk-stratify for Recurrence), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05097625 unknown statusnot on this map

A Prospective Cohort Study of Patients With Radically Treated Newly Diagnosed Locally Advanced HPV Negative Head and Neck Cancer to Develop and Validate a Multimodal Signature to Risk-stratify for Recurrence

TypeobservationalSponsorUniversity College, LondonRan2023 to 2026Enrolled200ConditionsHead and Neck Cancer
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Sanjena MithraUniversity College London, London, UK.ORCID http://orcid.org/0000-0002-5462-325X
Ahmed Abdullah AhmedComprehensive Cancer Centre, King's College London, London, UK.ORCID http://orcid.org/0000-0002-0409-7589
Amit RoshanBarts Cancer Institute Centre for Cancer Cell and Molecular Biology, London, UK.
Paul R BarberKing's College London, London, UK.
Camila de Carvalho GomesComprehensive Cancer Centre, King's College London, London, UK.ORCID http://orcid.org/0000-0003-2094-8141
Ton CoolenSaddle Point Science, York, UK.
Elinor SawyerSchool of Cancer and Pharmaceutical Sciences, King's College London Faculty of Life Sciences and Medicine, London, UK.
Nitzan RosenfeldBarts Cancer Institute Centre for Cancer Cell and Molecular Biology, London, UK.
Ralph SinkusDepartment of Biomedical Engineering and Imaging Science, King's College London, London, UK.
Miguel Reis-FerreiraKing's College London, London, UK.
Steve ConnorNeuroradiology, Guy's and St Thomas' Hospitals NHS Trust, London, UK.
Karin ShmueliDepartment of Medical Physics and Biomedical Engineering, University College London, London, UK.
Simon MorleyUniversity College London Hospitals NHS Foundation Trust, London, UK.
Pablo NenclaresBarts and The London NHS Trust, London, UK.
Caroline ApseyBarts and The London NHS Trust, London, UK.
Allan HackshawCR UK & UCL Cancer Trials Centre, London, UK.
Asit AroraGuy's and St Thomas' Hospitals NHS Trust, London, UK.
Teresita BeestonUniversity College London Hospitals NHS Foundation Trust, London, UK.
Juel TuazonUniversity College London Hospitals NHS Foundation Trust, London, UK.
Michelle BerinUniversity College London Hospitals NHS Foundation Trust, London, UK.
Antonia YeungUniversity College London Hospitals NHS Foundation Trust, London, UK.
Chris CurtisThe Swallows Head and Neck Cancer Charity, Blackpool, UK.
Kenrick NgDepartment of Medical Oncology, St Bartholomew's Hospital, London, UK.
Rami MustaphaComprehensive Cancer Centre, King's College London, London, UK.
Cheryl GillettKing's Health Partners Cancer Biobank, King's College London, London, UK.
Balqiisa IssaUCL, London, UK.
Chris Brew-GravesDivision of Surgery and Interventional Science, University College London, London, UK.
Maria LioumiKing's College London, London, UK.
Tony NgComprehensive Cancer Centre, King's College London, London, UK.
Martin ForsterUCL Cancer Institute, London, UK m.forster@ucl.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHead and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer globally, with over 12 000 new cases annually in the UK. Despite aggressive radical treatment, approximately 50% of patients with locally advanced (stage III/IV), human papilloma virus (HPV)-negative disease relapse within 2 years, often in the first year. Although current post-treatment follow-up schedules are recommended by clinical guidelines, imaging surveillance is led by symptoms after the initial 3 months and reliable biomarkers for early relapse are lacking. Consequently, recurrences are frequently detected too late for surgical salvage, though timely surgery can improve survival by up to 73% in selected cases. Head and Neck Early Relapse Detection Study represents a large-scale, prospective effort to integrate imaging, genomic, immunologic and microbiome datasets for relapse risk stratification and post-treatment surveillance in this high-risk patient group. METHODS AND ANALYSIS: Design: Prospective, observational cohort study.

settingSecondary and tertiary NHS hospitals in the UK.

participantsRecruiting up to 200 patients with stage III/IV (high-risk) HPV-negative HNSCC. Participants are enrolled into discovery (n=100) and validation (n=100) cohorts. Patients with HPV-positive tumours, metastatic disease or other contraindications defined in the protocol will be excluded.

interventionsObservational study with no experimental intervention. Participants are followed for 2 years with longitudinal collection of blood, saliva, urine, stool, fresh and archival tumour tissue and advanced MRI where possible in addition to their standard of clinical care. PRIMARY OUTCOMES: Development and independent validation of a multimodal recurrence risk prediction model. SECONDARY OUTCOMES: Identifying patient populations for primary treatment stratification, establishment of a longitudinal biorepository and identifying biological mechanisms of recurrence. Multimodal data will be integrated using machine learning and Bayesian modelling. ETHICS AND DISSEMINATION: Ethical approval was granted by the Bromley Research Ethics Committee (21/PR/1581). Findings will be disseminated through peer-reviewed publications, conference presentations and scientific meetings. TRIAL REGISTRATION NUMBER: NCT05097625.

Indexed as

Early Detection of CancerHead and Neck NeoplasmsNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckFemaleHuman Papillomavirus VirusesHumansMaleMultimodal ImagingProspective StudiesResearch DesignUnited KingdomEarly Detection of CancerGenomic MedicineHead & neck imagingHead & neck tumoursIMMUNOLOGYMachine Learning

Identifiers

PMID42785937
PMCPMC13629944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.